TABRECTA 150 MG
CAPMATINIB (CAPMATINIB HYDROCHLORIDE) : 150 MG · DIN 02527391 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is TABRECTA?
TABRECTA 150 MG contains CAPMATINIB (CAPMATINIB HYDROCHLORIDE) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02527391, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Sep-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TABRECTA used for?
Treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring MET exon 14 skipping alterations.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02527391 |
|---|---|
| Brand name | TABRECTA |
| Generic / active ingredient | CAPMATINIB (CAPMATINIB HYDROCHLORIDE) : 150 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 150 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EX17 CAPMATINIB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Sep-2022 |
| Original market date | 2022-09-16 00:00:00 |
How is it administered?
Recommended dose is 400 mg orally twice daily with or without food. Tablets must be swallowed whole. Continue until disease progression or unacceptable toxicity.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (Section 11 is listed in TOC but text ends before section).
How is it supplied?
150 mg and 200 mg tablets in blister packaging: 12 blisters/card, 5 or 10 cards/carton (60 or 120 tablets).
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious warnings: Interstitial lung disease (ILD)/Pneumonitis (can be fatal), Hepatotoxicity, and Embryo-fetal toxicity. Risk of photosensitivity and pancreatic enzyme elevations.
What can be used instead?
Other Canadian products sharing ATC code L01EX17 CAPMATINIB. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TABRECTA | 200 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02527405 |
Who else supplies CAPMATINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CAPMATINIB appears in 7 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.